Swiss - Delayed Quote CHF

Basilea Pharmaceutica AG (BSLN.SW)

40.25

-0.30

(-0.74%)

At close: April 25 at 5:31 PM GMT+2

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2023. At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the f

GlobeNewswire yesterday

BPMUF
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The grant award is to support initial p

GlobeNewswire 16 days ago

BPMUF
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the US Food and Drug Administration (FDA) approved ZEVTERA® (ceftobiprole medocaril sodium for injection), for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), i

GlobeNewswire 21 days ago

BPMUF
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s

GlobeNewswire last month

BPMUF
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio

Increased Cresemba® and Zevtera®-related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million and net profit of CHF 10.5 million, significantly above guidanceAddition of three new anti-infective assets to clinical portfolio, including phase-3-ready antifungal fosmanogepixStrong cash and restricted cash position of CHF 64.3 million, after fully absorbing investments into portfolio expansion and accelerated debt reduction FY 2024 guidance:

GlobeNewswire 2 months ago

BPMUF
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

Allschwil, Switzerland, January 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the sales of the antifungal Cresemba® (isavuconazole) in 2023 by its partner Knight Therapeutics Inc. (“Knight”, TSX: GUD) in Latin America exceeded the threshold triggering the first sales milestone payment for this region. David Veitch, Chief Executive

GlobeNewswire 3 months ago

BPMUF
Basilea announces acquisition of preclinical antibiotics program from Spexis

Novel class of antibioticsBactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strains Allschwil, Switzerland, January 15, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Spexis AG (SIX: SPEX) for a preclin

GlobeNewswire 3 months ago

BPMUF
Basilea provides portfolio status update

Clinical portfolio substantially strengthened through business development in 2023; two phase 3 studies expected to start in 2024Cresemba in-market sales of USD 445 million, increased 22% year-on-year, in 12-month period ending September 2023; 6-months market exclusivity extension granted in the USFDA PDUFA target action date on ceftobiprole US NDA April 3; US commercialization partner expected to be announced prior to FDA decision Allschwil, Switzerland, January 5, 2024 Basilea Pharmaceutica Lt

GlobeNewswire 3 months ago

BPMUF
Basilea announces accelerated loan repayment

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it will accelerate the repayment of its senior secured loan. The senior secured loan from Athyrium Capital Management, LP (“Athyrium”) had an initial total amount of CHF 75 million and a two-year term from Septe

GlobeNewswire 4 months ago

BPMUF
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis

Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. (“Astellas”) received the approval of Cresemba® (isavuconazole) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients by the US Food and Drug Administration (FDA

GlobeNewswire 4 months ago

BPMUF
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

Allschwil, Switzerland, November 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region and China exceeded the sales threshold triggering a further USD 1.25 million milestone

GlobeNewswire 5 months ago

BPMUF
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 13, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc., to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. In add

GlobeNewswire 5 months ago

BPMUF
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Exclusive license to evaluate tonabacase in preclinical studiesExclusive option to license tonabacase at pre-agreed terms Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, October 31, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company, committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive evaluation license and option agreement for tonabacase,

GlobeNewswire 5 months ago

BPMUF
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections

New compound added to Basilea’s clinical pipeline; upon successful completion of preclinical profiling, start of phase 2 study planned for H1 2025Upfront payments of USD 2 million Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, October 19, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset pur

GlobeNewswire 6 months ago

BPMUF
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Eight presentations on antibiotic ceftobiprole providing further evidence for its activity against methicillin-resistant Staphylococcus aureus (MRSA) and other clinically relevant pathogens Allschwil, Switzerland, October 17, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that scientific presentations with new data on its antibiotic ceftobip

GlobeNewswire 6 months ago

BPMUF
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole

Seeking approval for Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP)Prescription Drug User Fee Act (PDUFA) goal date set for April 03, 2024 Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, October 02, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal inf

GlobeNewswire 6 months ago

BPMUF
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Allschwil, Switzerland, September 28, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine (NEJM), one of the world's leading peer-reviewed medical journals.1 In the study, Basilea’s ceftobiprole, a beta-lactam antibiotic, was evaluated for

GlobeNewswire 6 months ago

BPMUF
Basilea reports strong revenue and profit growth in first half-year 2023

Increase in Cresemba® and Zevtera® related revenue to CHF 80.5 million (+57% year-on-year) Increase in operating profit to CHF 36.9 million and net profit to CHF 31.9 millionIncrease in cash and restricted cash to CHF 112.9 millionFull-year 2023 revenue and profit guidance increased Submitted US NDA for ceftobiprole in August Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 15, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical co

GlobeNewswire 8 months ago

BPMUF
Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

Seeking approval for Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP)NDA eligible for Priority Review Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 04, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has su

GlobeNewswire 8 months ago

BPMUF
Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, June 08, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported today that sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer in Europe and the Asia Pacific and China regions, respectively, exceeded thresholds that triggered two separate milestone payments totali

GlobeNewswire 10 months ago

BPMUF

Performance Overview

Return	BSLN.SW	MSCI WORLD
YTD	+14.02%	+4.38%
1-Year	-8.11%	+17.02%
3-Year	-13.77%	+12.28%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Basilea Pharmaceutica AG (BSLN.SW)

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio

Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

Basilea announces acquisition of preclinical antibiotics program from Spexis

Basilea provides portfolio status update

Basilea announces accelerated loan repayment

Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole

Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Basilea reports strong revenue and profit growth in first half-year 2023

Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea

Performance Overview